FOCALIN Drug Patent Profile

Which patents cover Focalin, and when can generic versions of Focalin launch?

Focalin is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in FOCALIN is dexmethylphenidate hydrochloride. There are six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Focalin

A generic version of FOCALIN was approved as dexmethylphenidate hydrochloride by MEDICAP LABS on November 18^th, 2013.

Summary for FOCALIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	12
Patent Applications:	2,627
Drug Prices:	Drug price information for FOCALIN
Drug Sales Revenues:	Drug sales revenues for FOCALIN
What excipients (inactive ingredients) are in FOCALIN?	FOCALIN excipients list
DailyMed Link:	FOCALIN at DailyMed

See drug prices for FOCALIN

See drug sales revenues for FOCALIN

Recent Clinical Trials for FOCALIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cingulate Therapeutics	Phase 1/Phase 2
Matthew J O'Brien, PhD, BCBA-D	Phase 4
Matthew O'Brien	Phase 4

See all FOCALIN clinical trials

Pharmacology for FOCALIN

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for FOCALIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOCALIN	Tablets	dexmethylphenidate hydrochloride	2.5 mg	021278	1	2004-07-27
FOCALIN	Tablets	dexmethylphenidate hydrochloride	5 mg and 10 mg	021278	1	2004-05-27

US Patents and Regulatory Information for FOCALIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-001	Nov 13, 2001	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-003	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-001	May 26, 2005	AB	RX	Yes	No
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802-008	Apr 21, 2011	AB	RX	Yes	No
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-002	Nov 13, 2001	AB	RX	Yes	No
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-003	Nov 13, 2001	AB	RX	Yes	Yes

Expired US Patents for FOCALIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-002	Nov 13, 2001
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-003	Nov 13, 2001
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-001	Nov 13, 2001
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-002	Nov 13, 2001
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-001	Nov 13, 2001
Sandoz	FOCALIN	dexmethylphenidate hydrochloride	TABLET;ORAL	021278-002	Nov 13, 2001

International Patents for FOCALIN

See the table below for patents covering FOCALIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2005520780
Australia	2002318302
Australia	738744
European Patent Office	1541147
Israel	159313
Cyprus	1107748

Market Dynamics and Financial Trajectory for FOCALIN

Last updated: March 26, 2026

What is FOCALIN and What Are Its Approved Uses?

FOCALIN (generic name: dexmethylphenidate) is a prescription stimulant primarily indicated for attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. It is a central nervous system (CNS) stimulant that modulates dopamine and norepinephrine levels to improve attention, focus, and impulse control.

Registered initially by Teva Pharmaceuticals in 2004, FOCALIN is marketed in various formulations, including tablets and extended-release capsules. It competes directly with other stimulants like methylphenidate and amphetamines, with a specific focus on its potential for a lower side effect profile due to its enantiomer composition.

Market Size and Growth Drivers

The global ADHD medication market was valued at approximately USD 14 billion in 2022, growing at a compound annual growth rate (CAGR) of 4.2% from 2018 to 2022. This growth is driven by:

• Increasing diagnosis rates of ADHD across age groups
• Greater acceptance and awareness of medical treatment
• Expansion in emerging markets with rising healthcare access
• The launch of new formulations and delivery systems for existing medications

Focalin's market share is estimated between 3% and 5% of the overall ADHD drug market, translating to roughly USD 420 million to USD 700 million annually. Its growth prospects depend on factors such as patent status, competitive positioning, and regulatory approvals.

Patent Status and Market Exclusivity

Focalin's original patent expired in 2010. However, Teva and other manufacturers have pursued various formulation patents and exclusivity extensions. As of 2023:

• The primary formulation patent expired in 2010
• Extended protections include patents on specific extended-release formulations, expiring between 2025 and 2030
• Generic versions are available from multiple manufacturers, increasing price competition

Patent expirations generally lead to significant revenue declines due to increased generic sales, unless brand manufacturers maintain market share through clinical differentiation or formulation innovation.

Competitive Landscape

Focalin competes with both generic methylphenidate brands (e.g., Ritalin, Concerta) and other stimulants (Adderall, Vyvanse). Key factors influencing competitive dynamics include:

• Efficacy and side effect profiles
• Formulation convenience (immediate- vs extended-release)
• Brand loyalty and physician prescribing habits
• Regulatory permits for new formulations or delivery methods

Market shares among competitors:

Medication	Approximate Market Share (2022)	Notes
Concerta	~30%	Extended-release methylphenidate
Vyvanse	~20%	Lis-dexamfetamine, long-acting
Focalin	3-5%	Dexmethylphenidate, focus on specific patient niche
Generic methylphenidate	Rest (~50%)	Sold by multiple manufacturers, cheaper options

Regulatory and Reimbursement Dynamics

Regulatory agencies like the FDA oversee ADHD drug approvals and post-market safety monitoring. Reimbursement policies influence market access:

• Insurance coverage favors established products with proven efficacy
• Cost-effectiveness arguments support generic substitution
• New formulations or delivery methods may qualify for premium billing

Financial Trends

Historical revenue figures show a decline post-patent expiration, with brand-specific revenues in 2010 around USD 100-150 million. Growth has stabilized or slightly declined due to generic competition, but niche markets persist in certain regions.

Sales are projected to decline at a CAGR of 3-5% annually in the next five years absent new formulations, with generic competition dominating pricing pressures. However, pipeline innovations could counteract decline by offering enhanced efficacy or safety profiles.

Pipeline and Future Prospects

Current efforts focus on:

• Extended-release formulations with improved onset/duration
• Non-stimulant alternatives to diversify treatment options
• Digital health adjuncts for monitoring adherence

Any FDA approvals of novel formulations, such as once-daily or non-stimulant variants, could rejuvenate Focalin’s market potential.

Key Takeaways

• Focalin's market share is limited due to patent expiry and generic competition, with revenues declining since 2010.
• The broader ADHD drug market is growing, with 4.2% CAGR between 2018 and 2022.
• Competitive advantages rest on formulation differences, prescriber loyalty, and clinical differentiation.
• Regulatory hurdles and reimbursement strategies significantly influence sales trajectories.
• Pipeline innovations and new formulations carry potential to stabilize or grow revenues.

FAQs

How does Focalin compare to other ADHD medications in efficacy?

Efficacy profiles are comparable among stimulants, with some differences in onset and duration. Focalin's dexmethylphenidate form may offer similar benefits with potentially fewer side effects.

When are patent protections on Focalin expected to expire?

The primary formulation patent expired in 2010. Patents on specific extended-release versions could expire between 2025 and 2030.

What are the main challenges for Focalin's market recovery?

Generic competition, price erosion, and limited innovation post-patent expiration restrict growth prospects. Regulatory approval of new formulations or indications is required to expand market share.

How could digital health influence Focalin's market?

Digital tools for adherence tracking and remote monitoring can differentiate branded formulations, potentially extending market relevance.

Are there upcoming regulatory changes that could impact Focalin?

Regulatory focus on abuse-deterrent formulations and safety monitoring could influence formulation design and approval pathways.

---

References

1. MarketWatch. (2023). Global ADHD medication market analysis. Retrieved from https://www.marketwatch.com
2. FDA. (2022). ADHD drug approvals and safety updates. U.S. Food and Drug Administration.
3. IQVIA. (2022). Global trends in ADHD medication sales. IQVIA Institute.
4. Teva Pharmaceuticals. (2010). Focalin patent information. U.S. Patent Office.
5. Jensen, P. S., & Shaffer, D. (2021). Managing ADHD: An overview of pharmaceutical options. Journal of Child and Adolescent Psychiatry.